Pyxis Oncology (NASDAQ:PYXS) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Key Points

• Wells Fargo raised Pyxis Oncology’s price target from $12 to $19 and maintained an “overweight” rating, implying potential upside of 392.23% from the stock’s reported price of $3.86.
• Analyst sentiment is broadly positive, with eight Buy ratings, one Hold, and one Sell; the consensus rating is “Moderate Buy,” with an average price target of $8.38.
• Pyxis Oncology reported a quarterly loss of $0.40 per share, missing the $0.35 consensus estimate. The clinical-stage biotechnology company is developing targeted cancer therapies, including antibody-drug conjugates.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) had its price objective lifted by analysts at Wells Fargo & Company from $12.00 to $19.00 in a report issued on Wednesday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Wells Fargo & Company's price target indicates a potential upside of 392.23% from the stock's current price.

A number of other equities research analysts also recently weighed in on PYXS. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Tuesday, August 18th. Weiss Ratings cut shares of Pyxis Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 30th. Leerink Partners decreased their target price on shares of Pyxis Oncology from $9.00 to $7.00 and set an "outperform" rating for the company in a research report on Thursday, July 2nd. Finally, Wall Street Zen cut shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $8.38.

Pyxis Oncology Price Performance

PYXS traded down $0.03 on Wednesday, reaching $3.86. 2,235,290 shares of the company traded hands, compared to its average volume of 858,992. The company has a market cap of $321.95 million, a price-to-earnings ratio of -2.74 and a beta of 1.34. The stock's 50 day moving average price is $3.00 and its 200-day moving average price is $2.20. Pyxis Oncology has a 52-week low of $1.03 and a 52-week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). As a group, equities research analysts forecast that Pyxis Oncology will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds have recently bought and sold shares of the company. Maia Wealth LLC acquired a new stake in shares of Pyxis Oncology in the fourth quarter valued at about $25,000. Fox Run Management L.L.C. acquired a new stake in Pyxis Oncology in the 4th quarter valued at approximately $26,000. Engineers Gate Manager LP acquired a new stake in Pyxis Oncology in the 4th quarter valued at approximately $26,000. LPL Financial LLC increased its position in Pyxis Oncology by 150.7% in the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company's stock worth $40,000 after buying an additional 21,100 shares during the period. Finally, XTX Topco Ltd bought a new position in Pyxis Oncology in the 2nd quarter worth approximately $40,000. 39.07% of the stock is currently owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.